MétaCan
Menu
Back to cohort
Record W4317233295 · doi:10.1111/jdv.18881

Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events

2023· review· en· W4317233295 on OpenAlexaff
Robert Bissonnette, Lawrence F. Eichenfield, Eric L. Simpson, Diamant Thaçi, Kenji Kabashima, Jacob P. Thyssen, Emma Guttman‐Yassky, Fabio P. Nunes, Margaret Gamalo, Faiz Ahmad, Michael E. Kuligowski, Kang Sun, C. Pipper, Anton Wulf Christensen, Pina D’Angelo, M. Milutinovic, Achim Guettner, Jonathan I. Silverberg

Bibliographic record

VenueJournal of the European Academy of Dermatology and Venereology · 2023
Typereview
Languageen
FieldMedicine
TopicDermatology and Skin Diseases
Canadian institutionsInnovaderm (Canada)
FundersSyddansk UniversitetNovartis PharmaRegeneron PharmaceuticalsSanofiPfizer
KeywordsMedicineAtopic dermatitisClinical trialHarmonizationIntensive care medicineExpert opinionClinical PracticeFamily medicineDermatologyPathology

Abstract

fetched live from OpenAlex

Despite the emergence of novel targeted treatments for atopic dermatitis (AD), there is a lack of guidelines on standardizing analysis of clinical trial data. To define and estimate meaningful treatment comparisons, several factors, including intercurrent events, must be taken into account. Intercurrent events are defined as events occurring after treatment initiation that affect either the interpretation or existence of the measurements associated with clinical questions of interest. Due to the relapsing, unpredictable nature of AD, intercurrent events frequently occur in AD trials, such as use of rescue therapy for intense itch and sleep deprivation. Despite the impact of intercurrent events in AD, they are often handled in an inconsistent manner across trials, which limits results interpretation. The estimand framework is increasingly used to estimate treatment effects while accounting for intercurrent events. This review explores how guidance from the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) on the use of estimands can be applied to support AD clinical trial design and analysis. We propose that estimands are used in AD trials and defined early during trial design. The use of estimands can provide clinicians with interventional trial results that are more reflective of clinical practice, help facilitate comparisons across clinical trials, and are more informative to enable improved treatment selection for patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.130
metaresearch head score (Gemma)0.330
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.870
Threshold uncertainty score0.688

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1300.330
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0080.008
Bibliometrics0.0030.003
Science and technology studies0.0000.003
Scholarly communication0.0060.005
Open science0.0060.003
Research integrity0.0070.011
Insufficient payload (model declined to judge)0.0090.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.327
GPT teacher head0.510
Teacher spread0.182 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designTheoretical or conceptual
DomainMethods
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the European Academy of Dermatology and VenereologySame topicDermatology and Skin DiseasesFrench-language works237,207